Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (XNCR) is a leading clinical-stage biopharmaceutical company headquartered in the United States, dedicated to the discovery and development of engineered monoclonal antibody and protein therapeutics. The primary goal of Xencor is to address severe and life-threatening diseases that currently have unmet medical needs, such as autoimmune diseases, asthma, and various forms of cancer.
Xencor leverages its proprietary XmAb® technology platform to enhance the natural immune functions of antibodies while maintaining a high degree of similarity to natural antibodies (over 99.5% identity). This innovative approach allows Xencor to create biotherapeutics that are more potent, safer, and longer-lasting, thereby improving patient outcomes and quality of life.
One of the key strengths of Xencor's XmAb technology is its ability to dramatically augment the immune functions of antibodies. This has resulted in a robust pipeline of product candidates, including eight in human clinical trials. Notable candidates in clinical development include XmAb5871 and XmAb7195, with several others such as XmAb14045 and XmAb662 in the pre-clinical stage. These candidates are being developed both by Xencor and in collaboration with pharmaceutical partners.
Financially, Xencor generates revenue through research and development collaborations and the licensing of its internally developed drug candidates. This collaborative approach not only advances their pipeline but also brings in essential funding to support ongoing and future projects.
Recently, Xencor has made significant strides in expanding its partnerships and advancing its clinical trials. These developments are crucial as they bring the company closer to delivering breakthrough treatments that can transform patient care in various therapeutic areas.
Overall, Xencor, Inc. stands out in the biopharmaceutical industry for its innovative approach to antibody and protein engineering, with a mission to fundamentally improve the treatment of serious diseases and enhance the quality of life for patients around the world.
Xencor, Inc. (NASDAQ:XNCR) and UCLA Technology Development Group have partnered to develop new therapeutic antibodies using Xencor's XmAb® technology. This collaboration aims to expedite the creation of innovative biologics, addressing previously challenging biological targets. Xencor's platforms allow for the production of bispecific antibodies and engineered cytokines, with 20 clinical-stage candidates currently advancing. Notably, two Xencor-engineered antibodies have already received FDA approval for treating severe blood disorders and non-Hodgkin lymphoma.
Xencor, Inc. (NASDAQ:XNCR) reported its financial results for Q4 and full year 2020, showing revenues of $41.9 million for Q4 and $122.7 million for the year, down from $3.5 million and $156.7 million in 2019, respectively. The company reported a net loss of $13.7 million for Q4, significantly improved from a $26.9 million loss in 2019, but a full-year net loss of $69.3 million compared to a profit of $26.9 million in 2019. Xencor plans to end 2021 with $425-$475 million in cash, supporting ongoing R&D initiatives, including studies of its bispecific antibodies.
Xencor, Inc. (NASDAQ:XNCR) will release its fourth quarter and full year 2020 financial results on February 23, 2021, after market closure. A conference call and webcast for discussion of the results and corporate updates will follow at 4:30 p.m. ET. Interested parties can access the call via phone or through the company's website. Xencor is engaged in developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, with 20 candidates in clinical development utilizing its XmAb technology.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences focused on oncology and healthcare.
- Guggenheim Healthcare Talks | 2021 Oncology Days: February 11-12, 2021, with a presentation on February 11 at 1:00 p.m. EST.
- 10th Annual SVB Leerink Global Healthcare Conference: February 22-26, 2021, with a presentation on February 24 at 3:00 p.m. EST.
Live webcasts will be available on the company's website, with replays for 30 days post-event.
Xencor (NASDAQ:XNCR) has entered a strategic research collaboration with MD Anderson Cancer Center to develop innovative CD3 bispecific antibody therapeutics aimed at cancer treatment. This partnership combines Xencor's XmAb® technology with MD Anderson's antibody research expertise. The collaboration includes preclinical development of undisclosed antibody candidates, with Xencor obtaining licensing options for potential new medicines. This initiative aims to advance antibody-based therapies that enhance immune responses against tumors, addressing an urgent need in cancer treatment.
Xencor, Inc. (NASDAQ:XNCR) has announced a research collaboration and license agreement with Janssen Biotech. This partnership focuses on developing XmAb bispecific antibodies targeting CD28 and a prostate tumor, aimed at treating prostate cancer. Xencor will receive an upfront payment of $50 million and potential future milestone payments and royalties on sales. Both companies will explore combination therapies using their respective drug candidate portfolios. The agreement is pending customary closing conditions, with expected completion by year-end.
Xencor, Inc. (NASDAQ:XNCR) reported updated data from a Phase 1 study of vibecotamab (XmAb®14045), a bispecific antibody targeting CD123 and CD3 in patients with relapsed or refractory acute myeloid leukemia (AML). Presenting at the 62nd ASH Annual Meeting, the results showed a 15% overall response rate with durable responses in some patients. The most common toxicity was mild-to-moderate cytokine release syndrome (CRS), affecting 61% of participants. Xencor's next steps include further development of vibecotamab, particularly in patient populations with minimal residual disease.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will participate in three major conferences. The Jefferies Virtual London Healthcare Conference is scheduled for November 17-19, 2020, with a presentation on November 19 at 5:00 p.m. GMT. The SVB Leerink Oncology Day will occur on the same day. Additionally, the Piper Sandler 32nd Annual Virtual Healthcare Conference is set for November 30 - December 3, 2020, with presentation availability starting on November 23. Webcasts will be available on Xencor's website after the events.
Xencor (NASDAQ: XNCR) has entered a clinical collaboration with MorphoSys AG and Incyte to evaluate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.
This partnership aims to accelerate the clinical development of plamotamab, which has shown promise in treating non-Hodgkin lymphoma. The Phase 1/2 study will be conducted in North America, Europe, and Asia-Pacific.
Xencor, Inc. (NASDAQ:XNCR) has presented new data from its preclinical XmAb bispecific antibody and IL-12-Fc cytokine programs at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This includes advancements in CD28 bispecific antibodies designed to co-stimulate T cells targeting tumor cells. The company showcased two selective TGFβ inhibitors and IL-12-Fc fusions, showing improved anti-tumor activity and potential benefits over existing therapies. Xencor continues to advance its innovative monoclonal antibody technology aimed at treating cancer and autoimmune diseases.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
What is Xencor, Inc.?
What is the XmAb technology?
What are some key products in Xencor's pipeline?
How does Xencor generate revenue?
Where is Xencor, Inc. based?
What diseases does Xencor target?
What makes Xencor's biotherapeutics unique?
Who are Xencor's partners?
What recent achievements has Xencor made?
What is the primary goal of Xencor?
